Industry News
Biotechnology Industry News

Pfizer accuses former employees of ‘treachery’ in stealing trade secrets to form Regor Therapeutics
Pfizer accuses former employees of 'treachery' in stealing trade secrets to form Regor Therapeutics aarmstrong Thu, 02/03/2022 - 09:29
Roche lets go of etro, dumping phase 3 Crohn’s prospect 18 months after posting weak colitis data
Roche lets go of etro, dumping phase 3 Crohn's prospect 18 months after posting weak colitis data ntaylor Thu, 02/03/2022 - 07:37
AstraZeneca punts midphase cardiovascular prospect to startup
AstraZeneca punts midphase cardiovascular prospect to startup ntaylor Thu, 02/03/2022 - 05:32
J&J discontinues work on eczema drug, leading to $610M in impairment charges for ex-XBiotech asset
J&J discontinues work on eczema drug, leading to $610M in impairment charges for ex-XBiotech asset klahucik Wed, 02/02/2022 - 16:58
J&J’s Janssen inks $1B biobucks pact for Mersana’s ADC tech in 3 targets
J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets klahucik Wed, 02/02/2022 - 16:20
Gilead’s CD47 clinical hold expands as CEO O’Day expresses ‘sense of urgency’ in getting trials back on track
Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track aarmstrong Wed, 02/02/2022 - 09:33
FDA puts LogicBio genome editing therapy trial on hold after 2nd infant suffers adverse event
FDA puts LogicBio genome editing therapy trial on hold after 2nd infant suffers adverse event ntaylor Wed, 02/02/2022 - 07:54
Novartis JAKs in rival to Incyte’s topical eczema drug after seeing clinical data
Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data ntaylor Wed, 02/02/2022 - 05:26
Doctor groups urge Biden administration to disclose costs of federally funded clinical trials
Doctor groups urge Biden administration to disclose costs of federally funded clinical trials klahucik Tue, 02/01/2022 - 10:27
Anavex touts ‘very large’ phase 3 win for Rett syndrome drug—2 weeks after moving study’s goalposts
Anavex touts 'very large' phase 3 win for Rett syndrome drug—2 weeks after moving study's goalposts aarmstrong Tue, 02/01/2022 - 10:27
UPDATE: Anavex touts ‘very large’ phase 3 win for Rett syndrome drug—2 weeks after moving study’s goalposts
UPDATE: Anavex touts 'very large' phase 3 win for Rett syndrome drug—2 weeks after moving study's goalposts aarmstrong Tue, 02/01/2022 - 10:27
Takeda shunts jewel of Shire takeover to new spinoff Oak Hill
Takeda shunts jewel of Shire takeover to new spinoff Oak Hill ntaylor Tue, 02/01/2022 - 08:21
As CEO goes, cash woes drive Sio to give Parkinson’s program the heave-ho
As CEO goes, cash woes drive Sio to give Parkinson's program the heave-ho ntaylor Tue, 02/01/2022 - 05:19
An ‘atlas’ of the brain spurs discovery of new cells that could provide map for stroke, Alzheimer’s treatments
An 'atlas' of the brain spurs discovery of new cells that could provide map for stroke, Alzheimer's treatments klahucik Mon, 01/31/2022 - 13:23
Leo Pharma picks Christophe Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme
Leo Pharma picks Christophe Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme klahucik Mon, 01/31/2022 - 12:14
Leo Pharma picks Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme
Leo Pharma picks Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme klahucik Mon, 01/31/2022 - 12:14
Led by Nanopore and Exscientia, UK startups snag half of Europe’s biotech VC funding in record-setting 2021
Led by Nanopore and Exscientia, UK startups snag half of Europe's biotech VC funding in record-setting 2021 klahucik Mon, 01/31/2022 - 10:14
Gamida Cell readies stem cell transplant therapy for FDA submission but seeks strategic partners amid staffing cuts
Gamida Cell readies stem cell transplant therapy for FDA submission but seeks strategic partners amid staffing cuts aarmstrong Mon, 01/31/2022 - 09:33
Madrigal’s NASH prospect clears first phase 3 test, raising hopes it can magic up positive pivotal efficacy data
Madrigal's NASH prospect clears first phase 3 test, raising hopes it can magic up positive pivotal efficacy data ntaylor Mon, 01/31/2022 - 08:54
Pfizer ends $3B drug dream despite phase 2b success, leaving Regeneron with a clear run at cardiovascular market
Pfizer ends $3B drug dream despite phase 2b success, leaving Regeneron with a clear run at cardiovascular market ntaylor Mon, 01/31/2022 - 08:04

